According to Globenewswire, BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to technological innovation and healthcare, announced that its board of directors has officially approved the company's new Ethereum-focused financial strategy. This decision marks BGLC as the first Nasdaq listed company to give Ethereum its exclusive priority as a strategic financial asset, and echoes the recent announcement that Ethereum has been included in the US "Strategic Reserves of Cryptocurrency". At the same time, BGLC released the Ethereum Strategy White Paper, detailing the reasons behind corporate decisions and the broader significance of Ethereum as a financial infrastructure asset. The white paper explores the adoption of Ethereum in institutions, staking capabilities, and upcoming protocol upgrades that consolidate Ethereum’s long-term value and practicality for enterprises.